{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:19:47Z","timestamp":1778620787059,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"am","delay-in-days":377,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019708","name":"UroGen Pharma","doi-asserted-by":"publisher","award":["2020-0776"],"award-info":[{"award-number":["2020-0776"]}],"id":[{"id":"10.13039\/100019708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH1710576"],"award-info":[{"award-number":["W81XWH1710576"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020772","name":"Office of Research, University of Georgia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020772","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.clgc.2023.06.010","type":"journal-article","created":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T17:33:04Z","timestamp":1687455184000},"page":"14-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A SEER-Medicare Based Quality Score for Patients With Metastatic Upper Tract Urothelial Carcinoma"],"prefix":"10.1016","volume":"22","author":[{"given":"Daniel D.","family":"Joyce","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1870-5805","authenticated-orcid":false,"given":"Courtney A.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Chamie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew D.","family":"Galsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen A.","family":"Boorjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2683-2185","authenticated-orcid":false,"given":"Stephen B.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vidit","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2023.06.010_bib0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"Ca-Cancer J Clin"},{"key":"10.1016\/j.clgc.2023.06.010_bib0002","unstructured":"National Institutes of Health: Genetic and rare disease information center. FAQs about rare diseases. https:\/\/rarediseases.info.nih.gov\/diseases\/pages\/31\/faqs-about-rare-diseases. Last updated: Jan 26 2021. Accessed: April 17, 2022."},{"key":"10.1016\/j.clgc.2023.06.010_bib0003","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.euo.2022.04.003","article-title":"Oncologic surveillance after radical nephroureterectomy for high-risk upper tract urothelial carcinoma","volume":"5","author":"Martini","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2023.06.010_bib0004","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00345-016-1928-x","article-title":"Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)","volume":"35","author":"Soria","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2023.06.010_bib0005","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jgo.2020.08.005","article-title":"Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma diagnosed between 2008 and 2012","volume":"12","author":"Dinan","year":"2021","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.clgc.2023.06.010_bib0006","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.urolonc.2009.03.021","article-title":"Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer","volume":"29","author":"Porter","year":"2011","journal-title":"Urol Oncol-Semin Ori"},{"key":"10.1016\/j.clgc.2023.06.010_bib0007","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1080\/13696998.2019.1591424","article-title":"Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma","volume":"22","author":"Aly","year":"2019","journal-title":"J Med Econ"},{"key":"10.1016\/j.clgc.2023.06.010_bib0008","first-page":"33","article-title":"The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy","author":"Hsieh","year":"2015","journal-title":"Urol Oncol-Semin Orig Investig"},{"key":"10.1016\/j.clgc.2023.06.010_bib0009","first-page":"163","article-title":"Do metastatic upper tract urothelial carcinoma and bladder carcinoma have similar clinical responses to systemic chemotherapy? A Japanese multi-institutional experience","volume":"46","author":"Kikuchi","year":"2016","journal-title":"Japanese J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.06.010_bib0010","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/bju.14756","article-title":"Palliative care in patients with bladder cancer: an opportunity for value improvement?","volume":"123","author":"McClintock","year":"2019","journal-title":"Bju Int"},{"key":"10.1016\/j.clgc.2023.06.010_bib0011","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/iju.13067","article-title":"Prognostic model to predict survival in patients with metastatic upper tract urothelial carcinoma treated with cisplatin-based chemotherapy","volume":"23","author":"Hsieh","year":"2016","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2023.06.010_bib0012","doi-asserted-by":"crossref","first-page":"E28","DOI":"10.1111\/bju.12133","article-title":"Patient characteristics and outcomes in metastatic upper tract urothelial carcinoma after radical nephroureterectomy: the experience of Japanese multi-institutions","volume":"112","author":"Tanaka","year":"2013","journal-title":"Bju Int"},{"key":"10.1016\/j.clgc.2023.06.010_bib0013","first-page":"39","article-title":"Impact of high-intensity local treatment on overall survival in stage IV upper tract urothelial carcinoma","author":"Paciotti","year":"2021","journal-title":"Urol Oncol-Semin Ori"},{"key":"10.1016\/j.clgc.2023.06.010_bib0014","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2020.0011","article-title":"Bladder Cancer, version 3.2020, NCCN Clinical Practice Guidelines in oncology","volume":"18","author":"Flaig","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clgc.2023.06.010_bib0015","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.eururo.2010.12.042","article-title":"European Guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update","volume":"59","author":"Roupret","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2023.06.010_bib0016","first-page":"1161","article-title":"Recommendations EAU 2001 - Guidelines on bladder cancer","volume":"12","author":"Oosterlinck","year":"2002","journal-title":"Prog Urol"},{"key":"10.1016\/j.clgc.2023.06.010_bib0017","doi-asserted-by":"crossref","first-page":"100225","DOI":"10.1016\/j.esmoop.2021.100225","article-title":"Care of the adult cancer patient at the end of life: ESMO Clinical Practice Guidelines","volume":"6","author":"Crawford","year":"2021","journal-title":"Esmo Open"},{"key":"10.1016\/j.clgc.2023.06.010_bib0018","unstructured":"Treatment and Care towards the End of Life, www.gmc-uk.org\/ethical-guidance\/ethical-guidance-for-doctors\/treatment-and-care-towards-the-end-of-life. Accessed: July 31, 2023."},{"key":"10.1016\/j.clgc.2023.06.010_bib0019","doi-asserted-by":"crossref","first-page":"75.e1","DOI":"10.1016\/j.urolonc.2020.06.010","article-title":"Clinicopathological characteristics, prognosis, and chemosensitivity in patients with metastatic upper tract urothelial carcinoma","volume":"39","author":"Li","year":"2021","journal-title":"Urol Oncol-Semin Ori"},{"key":"10.1016\/j.clgc.2023.06.010_bib0020","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/jjco\/hyy094","article-title":"Outcome and prognostic factors in metastatic urothelial carcinoma patients receiving second-line chemotherapy: an analysis of real-world clinical practice data in Japan","volume":"48","author":"Matsumoto","year":"2018","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.06.010_bib0021","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.annepidem.2007.03.011","article-title":"A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients","volume":"17","author":"Klabunde","year":"2007","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.clgc.2023.06.010_bib0022","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.21037\/tau-21-47","article-title":"Update on systemic treatment of upper tract urothelial carcinoma: a narrative review of the literature","volume":"10","author":"Gust","year":"2021","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.clgc.2023.06.010_bib0023","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1089\/jpm.2010.0347","article-title":"Identifying patients in need of a palliative care assessment in the hospital setting a consensus report from the center to advance palliative care","volume":"14","author":"Weissman","year":"2011","journal-title":"J Palliat Med"},{"key":"10.1016\/j.clgc.2023.06.010_bib0024","doi-asserted-by":"crossref","first-page":"E552","DOI":"10.1016\/S1470-2045(16)30577-0","article-title":"Referral criteria for outpatient specialty palliative cancer care: an international consensus","volume":"17","author":"Hui","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2023.06.010_bib0025","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.eururo.2016.11.012","article-title":"Efficacy of systemic chemotherapy plus radical nephroureterectomy for metastatic upper tract urothelial carcinoma","volume":"71","author":"Seisen","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2023.06.010_bib0026","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.euo.2020.11.005","article-title":"Incidence and survival rates of contemporary patients with invasive upper tract urothelial carcinoma","volume":"4","author":"Ruvolo","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2023.06.010_bib0027","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/abm\/kay077","article-title":"Impact of interdisciplinary outpatient specialty palliative care on survival and quality of life in adults with advanced cancer: a meta-analysis of randomized controlled trials","volume":"53","author":"Hoerger","year":"2019","journal-title":"Ann Behav Med"},{"key":"10.1016\/j.clgc.2023.06.010_bib0028","doi-asserted-by":"crossref","first-page":"780","DOI":"10.6004\/jnccn.2021.0033","article-title":"NCCN Guidelines(R) insights: palliative care, Version 2.2021","volume":"19","author":"Dans","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clgc.2023.06.010_bib0029","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s11255-016-1214-2","article-title":"Comparison of clinicopathological features in metastatic upper tract urothelial carcinoma and urothelial bladder cancer","volume":"48","author":"Xie","year":"2016","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.clgc.2023.06.010_bib0030","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1001\/jama.2010.258","article-title":"Availability and integration of palliative care at US cancer centers","volume":"303","author":"Hui","year":"2010","journal-title":"Jama-J Am Med Assoc"},{"key":"10.1016\/j.clgc.2023.06.010_bib0031","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/bju.14708","article-title":"Palliative care use amongst patients with bladder cancer","volume":"123","author":"Hugar","year":"2019","journal-title":"Bju Int"},{"key":"10.1016\/j.clgc.2023.06.010_bib0032","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.6004\/jnccn.2019.7319","article-title":"Trends and social barriers for inpatient palliative care in patients with metastatic bladder cancer receiving critical care therapies","volume":"17","author":"Mazzone","year":"2019","journal-title":"J Natl Compr Canc Ne"},{"key":"10.1016\/j.clgc.2023.06.010_bib0033","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/0825859720924936","article-title":"Trends and utilization of inpatient palliative care among patients with metastatic bladder cancer","volume":"36","author":"Han","year":"2021","journal-title":"J Palliat Care"},{"key":"10.1016\/j.clgc.2023.06.010_bib0034","doi-asserted-by":"crossref","first-page":"345.e1","DOI":"10.1016\/j.urolonc.2022.02.016","article-title":"Comparing costs of renal preservation versus radical nephroureterectomy management among patients with non-metastatic upper tract urothelial carcinoma","volume":"40","author":"Williams","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2023.06.010_bib0035","doi-asserted-by":"crossref","DOI":"10.1007\/s11606-022-07454-z","article-title":"Quality indicators for high-need patients: a systematic review","author":"Schneberk","year":"2022","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.clgc.2023.06.010_bib0036","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1056\/NEJMsb2031138","article-title":"CMS innovation center at 10 years - progress and lessons learned","volume":"384","author":"Smith","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clgc.2023.06.010_bib0037","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.juro.2015.05.002","article-title":"The power and the peril of large administrative databases","volume":"194","author":"Penson","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2023.06.010_bib0038","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.6521","article-title":"Accuracy and completeness of diagnosis codes for cancer metastasis on Medicare claims","volume":"31","author":"Chawla","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.06.010_bib0039","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","article-title":"Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial","volume":"395","author":"Birtle","year":"2020","journal-title":"Lancet"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323001507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323001507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:39:57Z","timestamp":1778618397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767323001507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1558767323001507"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2023.06.010","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A SEER-Medicare Based Quality Score for Patients With Metastatic Upper Tract Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2023.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}